Niacinamide for Health & Longevity

Created on 11/21/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Niacinamide, a vitamin B3 supplement studied against skin cancer, has its best human support for fewer new skin cancers in people with heavily sun-damaged skin and earlier skin cancer. The benefit fades once stopped and failed after organ transplant. Eye signals are early, slowing aging unshown in people. Mostly mild digestive side effects at skin-trial doses; low platelets on dialysis. A targeted skin-cancer measure, not an established longevity treatment. (Full Review)

Protocol

Skin cancer prevention (high-risk adults)
500 mg twice daily
Continuously; morning and evening with meals (common practice; no time-of-day comparison exists)
Glaucoma (investigational)
1.5 g/day for 6 weeks, then 3 g/day
1 g/day, then 2 g/day in normal-tension glaucoma
Upper limits
EU: 900 mg/day
US upper level of 35 mg/day covers all supplemental niacin, including nicotinamide
Time to effect
Skin cancers
Over 12 months
Fewer new skin cancers; no benefit remained after stopping
Actinic keratoses
Within 3 months
Fewer scaly precancerous sun-damage patches
Retinal electrical responses
Within 12 weeks
Glaucoma; electrical improvement without shown protection of vision

Benefits

Contraindications
  • Active liver disease
  • Hemodialysis patients outside nephrology supervision
  • Pregnancy and lactation above dietary intake
  • Unsupervised use above 3 g/day
Key Interactions
  • Carbamazepine: carbamazepine toxicity
  • Primidone: altered seizure control or sedation
  • Phosphate binders (sevelamer, calcium acetate): added thrombocytopenia, diarrhea, itching and anemia
  • Radiotherapy: altered radiation response and nausea
Theoretical (inferred from mechanism)
  • Other vitamin B3 forms (NR, NMN): added methyl-group demand and metabolite load
  • Liver-stressing drugs (methotrexate, valproate) and heavy alcohol use: liver-enzyme elevation
  • Anticoagulants and antiplatelets (warfarin, clopidogrel) in kidney failure: bleeding
  • Glucose-lowering drugs (metformin, insulin): weaker glucose control
  • PARP inhibitor cancer drugs (olaparib): unknown change in drug effect

Risk & Side Effects

  • High: Gastrointestinal upset and diarrhea; thrombocytopenia in kidney failure
  • Medium: Pruritus, anemia and herpes zoster in dialysis
  • Low: Liver injury at multi-gram doses; reduced insulin sensitivity; cardiovascular events via 4PY metabolite
  • Speculative: Sirtuin inhibition opposing longevity pathways; methyl-group drain

Monitoring

Marker Target Why
Platelet count 150–450 ×10⁹/L Falls with nicotinamide in kidney failure
ALT 7–56 U/L Liver injury at high doses
Serum creatinine with eGFR Creatinine 0.7–1.3 mg/dL Reduced clearance raises exposure and platelet risk
Fasting glucose 70–99 mg/dL Gram doses reduced insulin sensitivity
Serum phosphate (dialysis only) 2.5–4.5 mg/dL Falls with nicotinamide
Actinic keratosis and new skin cancer count No established target; change from own baseline count Lower counts during use
Visual field mean deviation (glaucoma only) No established target; rate of change from own baseline Under study
Carbamazepine or primidone drug level (users only) Not specified in the ER Nicotinamide slows their metabolism

Cadence: Baseline complete blood count, liver enzymes, kidney function and fasting glucose, plus a drug level with carbamazepine or primidone; blood tests at 8–12 weeks after starting or a dose increase, then every 6–12 months; skin examinations every 3–6 months; visual fields at the interval set by the treating ophthalmologist. Below 1,500 mg/day, routine adverse-effect monitoring may not be indicated.

Qualitative Assessment

  • Gastrointestinal comfort (nausea, loose stools, abdominal discomfort)
  • Easy bruising, nosebleeds or bleeding gums
  • New rough or scaly skin patches between examinations
  • Changes in vision, glare sensitivity or contrast
  • Itching or rash
  • Energy and general well-being